ASTANA, Kazakhstan, January 2. Kazakhstan plans
to build a full-cycle biopharmaceutical complex in the Alatau
Special Economic Zone, with total investments exceeding 103 billion
tenge ($203 million), Trend reports via the Kazakh government.
Prime Minister Olzhas Bektenov signed a decree approving the
investment agreement between the Ministry of Health and
Kazakhstan's Khan Tengri Biopharma company. The facility will
create more than 180 permanent jobs and aims to enhance domestic
pharmaceutical production.
The plant will be equipped to produce 58 types of medicines,
with a focus on manufacturing active pharmaceutical ingredients
(APIs). The production portfolio will include 27 international
non-patented drugs, particularly for oncology, autoimmune diseases,
rare conditions, and inflammatory disorders.
According to the government's statement, the project is
strategically significant for the country’s pharmaceutical sector,
supporting the shift towards local production and phased import
substitution of essential drugs. Some of the products will also be
exported to the Eurasian Economic Union (EAEU), CIS countries, and
the Middle East.
The initiative is part of President Kassym-Jomart Tokayev's
decree to increase Kazakhstan's domestic pharmaceutical production
to 50% of total market share.
Stay up-to-date with more news on Trend News
Agency's WhatsApp channel
